Ankylosing spondylitis: What is the cost to society, and can it be reduced?

Best Practice and Research: Clinical Rheumatology

Volumn 16, Issue 4, 2002, Pages 691-705

  Boonen, A ^a   Severens, J L ^b  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Ankylosing spondylitis; Cost of illness; Direct costs; Economic evaluation; Indirect costs; Spondyloarthropathies; Work

Indexed keywords

NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISOLONE; DISEASE MODIFYING ANTIRHEUMATIC DRUG;

ABSENTEEISM; ANKYLOSING SPONDYLITIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DRUG COST; DRUG EFFECT; ECONOMIC EVALUATION; EMPLOYMENT; EXERCISE; FUNCTIONAL DISEASE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; LONG TERM CARE; PHYSIOTHERAPY; PREVALENCE; PRIORITY JOURNAL; PRODUCTIVITY; REVIEW; RHEUMATIC DISEASE; SIDE EFFECT; SOCIETY; SOCIOECONOMICS; SPONDYLOARTHROPATHY; TOTAL HIP PROSTHESIS; WORK DISABILITY; ECONOMICS; ENTERITIS; HEALTH CARE PLANNING; HOSPITALIZATION; OSTEOPOROSIS;

COST OF ILLNESS; HUMANS; SOCIOECONOMIC FACTORS; SPONDYLITIS, ANKYLOSING;

EID: 0036730689     PISSN: 15216942     EISSN: None     Source Type: Journal    
DOI: 10.1053/berh.2002.0244     Document Type: Review

References (56)

1. Drummond MF & O'Brien BJ. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford Medical Publications, 1997.
2. Rice DP. Cost-of-illness studies: Fact or fiction? Lancet 1994; 344: 1519-1520.
3. Luce BR & Manning WG. Estimating costs in cost-effectiveness analyses. In Gold MR, Siegel JE, Russell LB & Weistein MC (eds) Cost-Effectiveness in Health and Medicine, pp 176-213. New York: Oxford University Press, 1996.
4. Drummond M. Cost-of-illness studies: A major headache? Pharmacoeconomics 1992; 2: 1-4.
5. Koopmanschap MA & Rutten FFH. A practical guide for calculating the indirect costs of disease. Pharmacoeconomics 1996; 10: 460-466.
6. Bonneux L, Barendregt JJ, Nusselder WJ & Der Maas PJ. Preventing fatal diseases increases healthcare costs: Cause elimination life table approach. British Medical Journal 1998; 316: 26-29.
7. Meerding WJ, Bonneux L, Polder JJ et al. Demographic and epidemiological determinants of healthcare costs in Netherlands: Cost of illness study. British Medical Journal 1998; 317: 111-115.
8. Severens JL & Habraken JM. The cost-of-illness of pressure ulcers in The Netherlands. Advances in Wound Care 2002, (in press).
9. Hartunian NS & Smart CN. The Incidence and Economic Costs of Major Health Impairments. Lexington MA: Lexington Books, 1981.
10. Van Roijen L, Essink Bot ML, Koopmanschap MA et al. Labor and health status in economic evaluation of health care. The Health and Labor Questionnaire. International Journal of Technology Assessment in Health Care 1996; 12: 405-415.
11. Severens JL, Mulder J, Laheij RJ & Verbeek AL. Precision and accuracy in measuring absence from work as a basis for calculating productivity costs in The Netherlands. Social Sciences Medicine 2000; 51: 243-249.
12. Thompson SG & Barber JA. How should cost data in pragmatic trials be analysed? British Medical Journal 2000; 320: 1197-2000.
13. Ward MM. Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis & Rheumatism 2002; 45: (in press).
14. Boonen A, Van Der Heijde D, Guillemin F et al. Health resource use in ankylosing spondylitis. A two year's follow-up. Annals of the Rheumatic Diseases 2000; 59 (supplement 1): 281, abstract.
15. Sailly JC & Lebrun T. Les conséquences économiques et sociales de la pelvispondylite rhumatismale. Revue d'Epidémiologie et de Santé Publique 1982; 30: 305-324.
16. Cooper NJ. Economic burden of rheumatoid arthritis: A systematic review. Rheumatology 2000; 39: 26-33.
17. Newhall-Perry K, Law NJ, Ramos B et al. Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Journal of Rheumatology 2000; 27: 1156-1163.
18. Yelin E, Herrndorf A, Truin L & Sonneborn D. A national study of medical care expenditures for musculoskeletal conditions. The impact of health insurance and managed care. Arthritis & Rheumatism 2001; 44: 1160-1169.
19. Boonen A, De Vet H, Van Der Heijde D & Van Der Linden S. Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review. Journal of Rheumatology 2001; 28: 1056-1062.
20. Boonen A, Chorus A, Miedema H et al. Employment, work disability, and work days lost in patients with ankylosing spondylitis: A cross sectional study of Dutch patients. Annals of the Rheumatic Diseases 2001; 60: 353-358.
21. Boonen A, Chorus A, Miedema H et al. Withdrawal from labour force due to work disability in patients with ankylooing spondylitis. Annals of the Rheumatic Diseases 2001; 60: 1033-1039.
22. Boonen A, Van Der Heijde D, Landewe R et al. Work status and productivity costs due to ankylosing spondylitis: Comparison among three European countries. Annals of the Rheumatic Diseases 2002; 61: (in press).
23. Barlow JH, Wright CC, Williams B & Keat A. Work disability among patients with ankylosing spondylitis. Arthritis Care Research 2001; 45: 424-429.
24. Ward M & Kuzis S. Risk factors for work disability in patients with ankylosing spondylitis. Journal of Rheumatology 2001; 28: 315-321.
25. Zink A, Braun J, Listing J & Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis. Results from the German rheumatological database. German Collaborative Arthritis Centers. Journal of Rheumatology 2000; 27: 613-622.
26. Roussou E, Kennedy LG, Garrett S & Calin A. Socioeconomic status in ankylosing spondylitis: Relationship between occupation and disease activity. Journal of Rheumatology 1997; 24: 908-911.
27. Nissila M, Isomaki HA, Kaarela K et al. Prognosis of inflammatory joint disease. A three year follow-up study. Scandinavian Journal of Rheumatology 1983; 12: 33-38.
28. Kaarela K, Lehtinen K & Luukkainen R. Work capacity of patients with inflammatory joint diseases. An eight-year follow-up study. Scandinavian Journal of Rheumatology 1987; 16: 403-406.
29. Lehtinen K. 76 patients with ankylosing spondylitis seen after 30 years of disease. Scandinavian Journal of Rheumatology 1983; 12: 5-11.
30. Guillemin F, Briancon S, Pourel J & Gaucher A. Long-term disability and prolonged sick leaves as outcome measurements in ankylosing spondylitis. Possible predictive factors. Arthritis & Rheumatism 1990; 33: 1001-1006.
31. Ramos-Remus C, Macias MA, Suarez-Almazor ME et al. Labor status and working-days lost in a consecutive sample of 103 patients with ankylosing spondylitis. Arthritis & Rheumatism 1997; 40 (supplement): 1392.
32. McGuigan LE, Hart HH, Gow PJ et al. Employment in ankylosing spondylitis. Annals of the Rheumatic Diseases 1984; 43: 604-606.
33. Gran JT & Husby G. Ankylosing spondylitis: A comparative study of patients in an epidemiological survey, and those admitted to a department of rheumatology. Journal of Rheumatology 1984; 11: 788-793.
34. Gran JT, Ostensen M & Husby G. A clinical comparison between males and females with ankylosing spondylitis. Journal of Rheumatology 1985; 12: 126-129.
35. Gran JT & Skomsvoll JF. The outcome of ankylosing spondylitis: A study of 100 patients. British Journal of Rheumatology 1997; 36: 766-771.
36. Urbanek T, Sitajova H & Hudakova G. Problems of rheumatoid arthritis and ankylosing spondylitis patients in their labor and life environments. Czechoslovak Medicine 1984; 7: 78-89.
37. Fellmann J, Kissling R & Baumberger H. Socio-professional aspects of ankylosing spondylitis in Switzerland. Zeitschrift für Rheumatologie 1996; 55: 105-113.
38. Edmunds L, Elswood J, Kennedy LG & Calin A. Primary ankylosing spondylitis, psoriatic and enteropathic spondyloarthropathy: A controlled analysis. Journal of Rheumatology 1991; 18: 696-698.
39. Wordsworth BP & Mowat AG. A review of 100 patients with ankylosing spondylitis with particular reference to socio-economic effects. British Journal of Rheumatology 1986; 25: 175-180.
40. Calin ABC & Taylor A. Striking relationship between social/occupational status and outcome in ankylosing spondylitis. Arthritis & Rheumatism 1996; 39 (supplement): 1373.
41. Chamberlain MA. Socioeconomic effects of ankylosing spondylitis. International Rehabilitation Medicine 1981; 3: 94-99.
42. Chamberlain MA. Socioeconomic effects of ankylosing spondylitis in females: A comparison of 25 female with 25 male subjects. International Rehabilitation Medicine 1983; 5: 149-153.
43. Ringsdal VS & Helin P. Ankylosing spondylitis-education, employment and invalidity. Danish Medical Bulletin 1991: 38: 282-284.
44. Lehtinen K. Working ability of 76 patients with ankylosing spondylitis. Scandinavian Journal of Rheumatology 1981; 10: 263-265.
45. Ramos-Remus C, Prieto-Parra RE, Michel-Diaz J et al. A five-year cumulative analysis of labor-status and lost working days in patients with ankylosing spondylitis. Arthritis & Rheumatism 1998; 1 (supplement): 1136.
46. Koopmanschap MA & Rutten FFH. The impact of indirect costs: The consequences of production loss or increased costs of production. Medical Care 1996; 34: DS59-DS68.
47. Merkesdal S, Ruof J, Schöffski O et al. Indirect medical costs in early rheumatoid arthritis. Composition of and change in indirect costs within the first three years of disease. Arthritis & Rheumatism 2001; 44: 528-534.
48. Van Tubergen A, Boonen A & Van Den Linden S. Hindrances in effecting insurances among Dutch ankylosing spondylitis patients. Annals of the Rheumatic Diseases 2001; 60: (supplement 1): 231.
49. Koopmanschap MA. Cost-of-illness studies. Useful for health policy? Pharmacoeconomics 1998; 14: 143-148.
50. Byford S, Torgerson DJ & Raftery J. Economic note: Cost of illness studies. British Medical Journal 2000; 320: 1335.
51. Rice DP. Cost of illness studies: What is good about them? Injury Prevention 2000; 6: 177-179.
52. Black DA & Pole JD. Priorities in biomedical research. Indices of burden. British Journal of Preventive and Social Medicine 1975; 29: 222-227.
53. Hodgson TA. Costs of illness in cost-effectiveness analysis. A review of the methodology. Pharmacoeconomics 1994; 6: 536-552.
54. Bloom BS, Bruno DJ, Maman DY & Jayadevappa R. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics 2001; 19: 207-213.
55. Bakker C, Hidding A, Van Der Linden S & Van Doorslaer E. Cost effectiveness of group physical therapy compared to individualized therapy for ankylosing spondylitis. A randomized controlled trial. Journal of Rheumatology 1994; 21: 264-268.
56. Van Tubergen A, Boonen A, Landewe R et al. Cost-effectiveness of combined spa-exercise therapy in ankylosing spondylitis. A randomised controlled trial. Arthritis Care Research 2002; 45: (in press).